AKT1 and cancer: Two specific miR-331-3p target sites have been identified within the 3′-untranslated region of HER2 mRNA, and transfection of miR-331-3p in cancer cells reduced the expression of HER2 and inhibited its downstream PI3K/AKT pathway21,24.